# Response Modifier (Arabinoxylan Rice Bran/MGN-3/Biobran) With Interferon-Alpha for HCV

> **NCT02690103** · PHASE2 · COMPLETED · sponsor: **Cairo University** · enrollment: 37 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** pegylated IFN
- **DIETARY_SUPPLEMENT:** Biobran
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT02690103
- **Lead sponsor:** Cairo University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2016-02-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02690103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02690103, "Response Modifier (Arabinoxylan Rice Bran/MGN-3/Biobran) With Interferon-Alpha for HCV". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02690103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*